DOI: 10.12890/2020_001751

Immune Thrombocytopenic Purpura in Patients with COVID-19

Authors

  • Sabine Revuz Hôpitaux Privés de Metz, Metz, France
  • Nathalie Vernier Hôpitaux Privés de Metz, Metz, France
  • Leilah Saadi Hôpitaux Privés de Metz, Metz, France
  • Julien Campagne Hôpitaux Privés de Metz, Metz, France
  • Sophie Poussing Hôpitaux Privés de Metz, Metz, France
  • François Maurier Hôpitaux Privés de Metz, Metz, France

francois.maurier@hp-metz.fr

Keywords

COVID-19, SARS-CoV-2, thrombocytopenia, intravenous immunoglobulins

Abstract

We described three COVID-19-infected patients with profound immune thrombocytopenia causing haemorrhagic mucocutaneous complications. We conclude that an immune mechanism was responsible as common causes were excluded. Since corticoids were considered harmful in the circumstances, the patients were successfully treated with intravenous immunoglobulins without later relapse.

View the entire article

Downloads

Published

2020-06-09

Issue

Vol. 7 No. 7 (2020)

Categories

How to Cite

1.
Revuz S, Vernier N, Saadi L, Campagne J, Poussing S, Maurier F. Immune Thrombocytopenic Purpura in Patients with COVID-19. EJCRIM [Internet]. 2020 Jun. 9 [cited 2026 Nov. 3];7(7). Available from: https://ejcrim.com/index.php/ejcrim/article/view/1751

Most read articles by the same author(s)